A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next ...

The biotech will cut 180 positions, or about two-thirds of its workforce, and discontinue development of its lead drug ...

Editas Medicine (NASDAQ:EDIT – Free Report) had its price objective trimmed by Evercore ISI from $7.00 to $5.00 in a report ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Fintel reports that on December 16, 2024, JP Morgan downgraded their outlook for Editas Medicine (NasdaqGS:EDIT) from Neutral ...

Truist and Stifel downgraded Editas Medicine Inc (NASDAQ:EDIT) to "hold" from "buy". While Truist removed its price target ...

Stifel Nicolaus cut shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a buy rating to a hold rating in a report ...

Shares of Editas, the gene-editing company were down 23% at $1.45 on Friday. Editas announced a strategic shift, ending its development of reni-cel and cutting its workforce by 65%. The company ...

The company had said in October said that it was looking to license out its ex vivo editor renizgamglogene autogedtemcel to ...

Buoyed by recent scientific progress in its in vivo pipeline, the Massachusetts-based firm is shifting focus to developing in ...

Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.08, a high estimate of $13.00, ...